RAS wild-type

P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Multiplex immunofluorescence staining demonstrated that BCL-xL inhibition effectively triggered apoptosis in heterogeneous PDX tumor slice models, including models harboring oncogenic BRAF mutations. Our findings suggest that cetuximab-resistant CRC retains apoptotic competence, and that BCL-xL inhibition serves as a robust alternative therapeutic strategy that is largely independent of the tumor mutational profile.

KRAS mutant non-sq LA-NSCLC is associated with inferior outcomes, largely driven by increased distant and brain metastases. Tumors with concurrent CDKN2A and/or STK11 alterations had the poorest outcomes. These findings support the evaluation of KRAS inhibitors in this high-risk stage III population.

P2, N=90, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine

P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

P1/2, N=178, Not yet recruiting, Shanghai Eastern Hospital; Nerviano Medical Science Shanghai Ltd.

Conversely, KRAS-wild-type cells preserve NAD+ influx via sufficient baseline succinyl-SLC25A51, which stabilizes SLC25A51 and enables sufficient succinate accumulation to drive hypoxia inducible factor 1 subunit alpha (HIF1α)-mediated compensatory NAD+ production during treatment. Our work reveals a KRAS-specific metabolic vulnerability and proposes a dual-inhibition therapy for KRAS-driven AML.

P1, N=194, Recruiting, Hefei TG ImmunoPharma Co., Ltd.

Within surgically treated patients, baseline CA19-9 emerged as the most informative prognostic marker, while traditional clinicopathologic variables showed limited discriminatory value. These findings highlight the importance of careful patient selection and support further prospective studies integrating molecular and biomarker-based strategies to refine prognostication and optimize surgical decision-making in RAS-WT mCRC.

Ion Chiricuta" between 2015 and 2024 with first-line FOLFOX/FOLFIRI plus panitumumab...In multivariate analysis, only bNLR remained independently associated with PFS. These results suggest that both baseline and dynamic NLR may serve as low-cost prognostic biomarkers in mCRC patients treated with anti-EGFR therapy.

After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy...After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery...As third-line therapy, he received pembrolizumab monotherapy...We encountered two patients with mCRC and EGFR gene amplification who responded to panitumumab monotherapy. EGFR gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of RAS status.

P3, N=464, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.